BioSpace News Archive

Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and digital solutions for the medical and consumer markets, announced it is planning to launch a digital healthcare subscription service in the USA under the brand name proBEAT™.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that it is anticipating delays in the completion of its CB4211 Phase 1b study for NASH and obesity. This delay is a result of a pause by some of the company’s clinical research organization partners in all of their activities related to the study in response t

GenoFAB Inc. recently announced it would partner with Decisions LLC to help accelerate biomedical research projects

ValGenesis, Inc. announced that a global biotechnology/chemical and pharmaceutical giant based in Europe has chosen ValGenesis’s cloud-based Validation Lifecycle Management System, to digitalize plant qualification and validation processes across multiple sites.

Hoth to receive equity stake in Isoprene, full license of VNLG 152 for field of Dermatology and royalties from Isoprene for all other fields including Oncology

In the wake of the global COVID-19 Lockdown, SpendEdge, a global procurement market intelligence firm, has announced the availability of a team of experts dedicated to addressing the emerging supply chain queries in the pharmaceutical industry.

Pendulum Therapeutics , an evidence-based microbiome company, announced today that veteran health care executive Heather Mason has joined its board of directors. A global executive with more than 25 years of experience in bringing novel pharmaceutical and consumer products to battle chronic diseases, including diabetes, Mason brings a wealth of expertise to Pendulum Therapeutics’ fast-growing business. Mason most recently served as executi

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), a company (i) that has developed medical foods and medical devices in the ocular health marketplace and (ii) that is developing condition-specific nutraceuticals that the Company believes will provide supportive health benefits to consumers, announced today its financial results for the year ended December 31, 2019.

Samsung Biologics (207940.KS) has appointed Eun Young Yang as vice president of business development for the company’s expanded CDO (contract development organization) business. “Eun is one

‘hzVSF v13 (humanized Virus Suppressing Factor; VSF)’, a treatment that can be used for a wide range of viral diseases developed by ImmuneMed, was administered on March 28th at Yonsei University Hospital to treat COVID-19 pneumonia patients.